Orthovita completes Cortoss IDE pilot
This article was originally published in The Gray Sheet
Vertebral compression fracture pain reduced 67% and spinal function increased 42% in a three-site, 20-patient Orthovita pilot study for Cortoss verteboplasty compound. Malvern, Penn.-based Orthovita also is enrolling patients for a second pilot study to assess Cortoss in kyphoplasty...
You may also be interested in...
Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.
Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA neuroscientist Andrew Shen.
The templates from the US agency provide guidance to manufacturers developing antibody tests for clinical or at-home use.